{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007951","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.378182+00:00","generated_at":"2026-06-02T02:22:48.414633+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Voyager Q1 net loss $11.3M; IND cleared for VY-TAU01; cash $400M to 2027","bullets":["Net loss of $11.3M vs net income of $124.0M in Q1 2023; collaboration revenue $19.5M down from $150.5M.","Cash, equivalents and marketable securities of $400.5M as of March 31, 2024; runway into 2027.","IND clearance from FDA for anti-tau antibody VY-TAU01 for Alzheimer's disease; Phase 1a dosing imminent.","Development candidates selected in GBA1 and Friedreich's Ataxia gene therapy programs with Neurocrine; $8M total milestones triggered.","Appointed Toby Ferguson, M.D., Ph.D., as Chief Medical Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007951","json":"https://secwatch.observer/filing/0001558370-24-007951.json","markdown":"https://secwatch.observer/filing/0001558370-24-007951.md","text":"https://secwatch.observer/filing/0001558370-24-007951.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000155837024007951/0001558370-24-007951-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000155837024007951/vygr-20240513x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:22:48.414633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9635bd04f0431230735c5d50e36fef135976af6d","claim":"Voyager Therapeutics, Inc. reported first quarter 2024 results: revenue $19.5 million, net income $11.3 million.","evidence_excerpt":"INDs for the GBA1 and Friedreich’s Ataxia gene therapy programs in 2025. ​ First Quarter 2024 Financial Results ​ ● Collaboration Revenues: Voyager had collaboration revenue of $19.5 million for the first quarter of 2024, compared to $150.5 million for the same period in 2023. The decrease was primarily due to the first quarter 2023 recognition of $69.5 million from","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640266/000155837024007951/0001558370-24-007951-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Revenue","value":"$19.5 million"},{"label":"Net income","value":"$11.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}